MS Validated Antibodies offers:
Only excellent antibodies validated in more than a thousand tissues
Only one antibody per target, which performs at least as well as its “best in class” competitor
Unique documentation of antibody performance
CPA1 (clone MSVA-601M) is a new marker for immunohistochemistry with very high sensitivity and specificity (>99%) for acinar cell carcinoma of the pancreas. A study on 15,680 tumors of >100 different tumor entities was recently published in the American Journal of Surgical Pathology.[1]
Acinar cell carcinoma of the pancreas makes up for only 1-2% of pancreatic tumors but is misdiagnosed in a considerable fraction of cases. Based on the data by Uhlig et al, the use of MSVA-601M results in a considerably safer distinction of this tumor entity.
The immunohistochemical visualization of CTLA-4 on formalin fixed tissues has so far been hindered by a relative lack of CTLA-4 antibodies suitable for immunohistochemistry.
In a recent study published in Laboratory Investigation by nature, researchers from the University of Hamburg have successfully analyzed 4582 tumor samples from 90 different tumor entities for quantification of CTLA-4 positive lymphocytes in formalin fixed archival tissues[2]
In their paper, Dum et al. utilized two antibodies including our newly developed clone MSVA-152R in combination with artificial intelligence to reliably count CTLA-4 positive cells. Based on these data, the antibody MSVA-152R has emerged as a highly useful tool for research on CTLA-4.
[1] Uhlig R et al. “Carboxypeptidase A1 (CPA1) Immunohistochemistry Is Highly Sensitive and Specific for Acinar Cell Carcinoma (ACC) of the Pancreas.” Am J Surg Pathol. 2022 Jan 1;46(1):97-104. PMID: 34889867
[2] Dum et al. “Semi-automated validation and quantification of CTLA-4 in 90 different tumor entities using multiple antibodies and artificial intelligence”. Lab Invest. 2022 Jan 29 PMID: 35091676.)
MSVA Catalog 2022 is available to download now.
